武汉康复得

Wuhan Comfort Biological Technology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for metabolic diseases, specifically focusing on kidney stones and gout. The company leverages its proprietary protein engineering and recombinant enzyme platform to create first-in-class treatments that address unmet needs in nephrology. Its lead candidate, KFD-101, is an oral recombinant oxalate decarboxylase enzyme designed to degrade oxalate in the intestinal tract, thereby preventing the formation of kidney stones in patients with hyperoxaluria. Additionally, the company is advancing a pipeline of small molecule inhibitors targeting urate transporters to treat hyperuricemia and gout. Wuhan Comfort aims to provide non-invasive, effective solutions for chronic metabolic conditions through its specialized enzyme technology.